史达手术
估值 各估值倍数与自身5年区间的对比
同业对比 Medical Instruments & Supplies
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| 史达手术 (STAA) | 1.07B | 265.88 | 2.92 | 0.00% |
| Intuitive Surgical (ISRG) | 150.74B | 48.93 | 8.30 | 0.00% |
| Becton Dickinson & Co (BDX) | 52.23B | 57.93 | 2.14 | 2.19% |
| ResMed (RMD) | 33.61B | 22.91 | 5.10 | 1.00% |
| Alcon (ALC) | 31.99B | 50.52 | 1.48 | 0.53% |
| Medline (MDLN) | 31.55B | 68.24 | 2.73 | 0.00% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价低于晨星合理价值估算30.9%。
合理价值
Staar Surgical Co receives a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 20% discount to our quantitative fair value estimate of $27.83 per share; however, caution is warranted due to this estimate's high uncertainty rating.
The company's profitability increases our estimated fair value. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. Reflecting the firm's profitability is its enterprise value to free cash flow ratio of 14.3, which ranks in the bottom 30% compared with global peers. This can be a sign of operational efficiency and potential for the company to fund growth, pay dividends, or reduce debt without needing additional capital. We believe this is a sign that shares could be undervalued.
On a different note, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 0.9, for example, ranks in the bottom 30% compared with global peers. The market value of equity makes up a large fraction of enterprise value, indicating that shares have sharply risen, or that the company has a "lazy" balance sheet that is underleveraged. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has been a laggard relative to the broader universe over the past year. This underperformance makes the stock appear cheap, which portends a buying opportunity in light of other contributors to our model.
经济护城河
With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
作者:Quantitative Equity Report
报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
史达手术 讨论区 0 条评论